Axsome Therapeutics (NASDAQ:AXSM)报告季度每股亏损$(1.54)，未达到分析师普遍预期的$(1.03)，差距为49.51%。相比去年同期每股亏损$(2.08)，这是一个25.96%的改善。公司报告季度销售额为$1.1877亿，超出分析师普遍预期的$1.1764亿，超出幅度为0.95%。相比去年同期的$7153万，销售额增长了66.03%。

以上内容来自Benzinga Earnings专栏，原文如下：

Axsome Therapeutics (NASDAQ:AXSM) reported quarterly losses of $(1.54) per share which missed the analyst consensus estimate of $(1.03) by 49.51 percent. This is a 25.96 percent increase over losses of $(2.08) per share from the same period last year. The company reported quarterly sales of $118.77 million which beat the analyst consensus estimate of $117.64 million by 0.95 percent. This is a 66.03 percent increase over sales of $71.53 million the same period last year.